Generic Drugs

Pfizer settles with Teva on patents covering cancer medicine and antibiotic

Published in Drug Law Weekly, December 19th, 2006

Pfizer has reached a comprehensive agreement with generic drug manufacturer Teva that resolves two separate lawsuits alleging patent infringement of Pfizer's cancer medication, Idamycin, and its antibiotic, Zithromax.

As part of the settlement, Teva will pay up to $70 million to Pfizer, which includes an option in 2007 for Teva to sell its own generic version of epirubicin, another cancer medication, prior to the August 2007 patent expiry. In addition, Teva will not contest the validity of the patents.

The agreement will end litigation by Pfizer against Teva and Sicor, a company owned by Teva, over Sicor's sales of idarubicin (the active ingredient...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2006-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry